Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma
Background The clinical response to immune checkpoint inhibitors (ICIs) in only part of the treated patients, in conjunction with the potentially serious side effects associated with this type of therapy, has emphasized the need to identify biomarkers to select patients who may benefit from ICI trea...
Saved in:
| Main Authors: | Timea Balatoni, Soldano Ferrone, Judit Olah, Andrea Ladányi, Eszter Papp, Anita Mohos, Anita Varga, Zsuzsanna Lengyel, Gabriella Emri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000209.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain
by: Jacob Ruzevick, et al.
Published: (2013-01-01) -
Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer
by: Wilko Weichert, et al.
Published: (2022-03-01) -
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma
by: Julie Williamson, et al.
Published: (2025-02-01) -
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab
by: Jiajia Chen, et al.
Published: (2025-12-01) -
Identification of genetic fingerprint of type I interferon therapy in visceral metastases of melanoma
by: Laura Vízkeleti, et al.
Published: (2024-11-01)